Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 40.5mg equivalent to carbidopa 37.5 mg;  ; entacapone 200mg; levodopa 150mg - film coated tablet - 150mg/37.5mg/200mg - active: carbidopa monohydrate 40.5mg equivalent to carbidopa 37.5 mg   entacapone 200mg levodopa 150mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 54.1mg equivalent to 50 mg carbidopa;  ; entacapone 200mg; levodopa 200mg - film coated tablet - 200mg/50mg/200mg - active: carbidopa monohydrate 54.1mg equivalent to 50 mg carbidopa   entacapone 200mg levodopa 200mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red magnesium stearate   maize starch mannitol polysorbate 80 povidone purified water   sucrose titanium dioxide - latest regulatory activity

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 13.5mg equivalent to carbidopa 12.5 mg;  ; entacapone 200mg; levodopa 50mg - film coated tablet - 50mg/12.5mg/200mg - active: carbidopa monohydrate 13.5mg equivalent to carbidopa 12.5 mg   entacapone 200mg levodopa 50mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Нова Зеландия - английски - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 20.25mg equivalent to 18.75 mg carbidopa;  ; entacapone 200mg; levodopa 75mg - film coated tablet - 75mg/18.75mg/200mg - active: carbidopa monohydrate 20.25mg equivalent to 18.75 mg carbidopa   entacapone 200mg levodopa 75mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red magnesium stearate   maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - stalevo is indicated for the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Ирландия - английски - HPRA (Health Products Regulatory Authority)

niche generics limited - entacapone - film coated tablet - 200 milligram - other dopaminergic agents

Малта - английски - Medicines Authority

wockhardt uk limited - entacapone - film-coated tablet - entacapone 200 mg - anti-parkinson drugs

Малта - английски - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - entacapone - film-coated tablet - entacapone 200 mg - anti-parkinson drugs

Европейски съюз - английски - EMA (European Medicines Agency)

orion corporation - entacapone - parkinson disease - anti-parkinson drugs - entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Европейски съюз - английски - EMA (European Medicines Agency)

orion corporation - entacapone - parkinson disease - anti-parkinson drugs - entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Европейски съюз - английски - EMA (European Medicines Agency)

teva pharma b.v. - entacapone - parkinson disease - anti-parkinson drugs - entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.